As we showed that COVID-19 convalescents are characterized by lower NCAM-1 serum concentrations than never-infected individuals, we suppose that the observed effect may be associated not with neurodegeneration but with possible immune system activity. This evidence concerns the gene NCAM1 and COVID-19.